Masimo Co. (NASDAQ:MASI) Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 14.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,305 shares of the medical equipment provider's stock after selling 1,980 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Masimo were worth $1,869,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of Masimo by 19.8% during the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock worth $1,338,509,000 after acquiring an additional 1,340,836 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Masimo by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock worth $758,182,000 after acquiring an additional 66,215 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Masimo by 80.5% during the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock worth $405,807,000 after acquiring an additional 1,094,647 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Masimo by 119.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock worth $286,823,000 after acquiring an additional 943,001 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its stake in shares of Masimo by 8.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,662,376 shares of the medical equipment provider's stock worth $274,791,000 after acquiring an additional 135,888 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Raymond James lowered their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. BTIG Research set a $193.00 price target on shares of Masimo and gave the stock a "buy" rating in a report on Wednesday, May 7th. Wells Fargo & Company cut their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $200.00 price target (down previously from $215.00) on shares of Masimo in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $191.60.

Insider Activity at Masimo

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the sale, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. The trade was a 11.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Bilal Muhsin sold 10,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $163.28, for a total value of $1,632,800.00. Following the transaction, the chief operating officer now owns 24,172 shares in the company, valued at approximately $3,946,804.16. This represents a 29.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,053 shares of company stock valued at $6,998,565. 9.70% of the stock is owned by company insiders.

Masimo Stock Performance

Shares of NASDAQ MASI traded down $1.56 during midday trading on Wednesday, reaching $155.70. 57,603 shares of the stock were exchanged, compared to its average volume of 649,458. The firm has a market cap of $8.44 billion, a price-to-earnings ratio of 107.02 and a beta of 1.23. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $194.88. The firm has a 50-day simple moving average of $157.73 and a two-hundred day simple moving average of $167.26. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $372.00 million for the quarter, compared to analysts' expectations of $367.79 million. During the same quarter last year, the company earned $0.77 EPS. The firm's revenue for the quarter was down 24.5% compared to the same quarter last year. As a group, analysts anticipate that Masimo Co. will post 4.1 EPS for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.